New drug study aims to see how liver health affects medication
NCT ID NCT07401862
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study is testing a single dose of the drug eloralintide in 36 people with different levels of liver function—from healthy to severely impaired. Researchers want to see how the body absorbs and processes the drug and whether it causes side effects. The goal is to understand how liver damage might change the way the drug works, which could help guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eloralintide (LY3841136)
What this could lead to
If successful, this study will help determine safe dosing of eloralintide for people with liver problems, potentially guiding future treatment use.
What could go wrong
This is a very early Phase 1 study with only 36 participants. It is designed to measure drug levels and safety, not to treat any disease. Results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-••••
Contact
-
CRU Early Phase Unit
RECRUITINGKistarcsa, H-2143, Hungary
Contact Phone: •••-•••-••••
Contact
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
Contact